Find your path to Charity
410 people in our graph share verified history with Charity — schools, employers, funds. One of them is your warm intro.
Reid HuberunlockedCharity: together at Bellicum Pharmaceuticals, Inc. (2018–2023)
×5Charity: together at Amgen
×3Charity: together at Hamilton College
×2Charity: together at AbbVie
Executive at Outpace Bio
Intro paths
→
In turn, Charity can intro founders to Outpace Bio's investors below.
Outpace Bio's investors · 8
Abstract VenturesSan Francisco · $250K – $750K checks · since 2024Artis VenturesSan Francisco · $50K – $25M checks · since 2024Atinum Investment Co. Ltd.Seoul · $100K – $2M checks · since 2024Civilization Ventures Management, LlcTiburon · $1M – $10M checks · since 2024Mana VenturesEstero · since 2024Modi VenturesHouston · since 2024Playground GlobalPalo Alto · $1M – $20M checks · since 2024RA CapitalBoston · since 2024
Co-founders at Outpace Bio
ML
Marc LajoieCo-founder & Chief Executive Officer
SB
Scott BoykenCo-founder & Chief Technology Officer
SR
Stanley RiddellCo-Founder and Scientific Advisor
Experience
- Outpace BioChief Development Officercurrent2024 — presentSeattle, Washington, United States
- Sugar Tree Clinical Consulting, LLCPrincipal and Owner2023 — 2024San Francisco Bay Area
- Bellicum Pharmaceuticals, Inc.Chief Development Officer2021 — 2023
- Bellicum Pharmaceuticals, Inc.VP Clinical Development and Medical Affairs2019 — 2021South San Francisco, CA
- Bellicum Pharmaceuticals, Inc.Sr Dir US and Global Medical Affairs2018 — 2019South San Francisco, CA
- ACELYRIN, INC.VP Business and Development Operations2020 — 2021
- AbbVieSenior Director Oncology Clinical Development2018South San Francisco, CA
- AbbVie Stemcentrx an Abbvie CompanyScientific Director Oncology Clinical Development2016 — 2018South San Francisco, CA
- Pharmacyclics, an AbbVie CompanyAssociate Director Clinical Science2015 — 2016Sunnyvale, CA
- Pharmacyclics GmbH, an AbbVie CompanyAssociate Director Clinical Science2015Schaffhausen, Switzerland
- AmgenInternational Oncology Scientific Affairs, Heme/Onc TA Lead2010 — 2014Zug, Switzerland
- AmgenGlobal Oncology Scientific Affairs, SrMgr2008 — 2010Thousand Oaks, CA
- AmgenEarly Development - Oncology Phase 1 Research2006 — 2008Thousand Oaks, CA
- National Cancer InstituteClinical Pharmacology Research Core, Clinical Drug Development Fellow2004 — 2006Bethesda, Maryland
- Dartmouth Hitchcock Medical CenterOncology Pharmacist2002 — 2004Hanover, NH
- Mylan Bertek PharmaceuticalsIntern1992 — 1996
Skills & more
Publication PlanningOncologyHematologyScience CommunicationClinical ResearchScienceClinical PharmacologyDrug DevelopmentPharmaceutical IndustryBiotechnologyClinical TrialsClinical Development
+11 more
Life SciencesBiopharmaceuticalsInfectious DiseasesCancerMedical WritingOncology Clinical ResearchStrategic CommunicationsImmunologyLifesciencesMedicineGood Clinical Practice (GCP)From Charity's professional profile.
Frequently asked questions
- Who is Charity Scripture?
- Executive Officer at Outpace Bio
- Where does Charity Scripture work?
- Charity Scripture is Executive at Outpace Bio.
- Where did Charity Scripture go to school?
- Charity Scripture studied at Hamilton College (B.S., Biochemistry/Molecular Biology); Geisel School of Medicine at Dartmouth (M.S., Pharmacology and Toxicology); The University of North Carolina at Chapel Hill (PharmD).
Same school
Also attended Hamilton College92
Dan BartusPartner, Head of Research at Felicis VenturesDavid BloodFounding Partner and Senior Partner at Generation Investment ManagementDaniel GlassManaging Director, Global Market Research at Deerfield Management CompanySarah SommerCo-Founder and Partner at Level EquityJosh LabonteSenior Associate at Level EquityGeoff OblakGeneral Partner at Data Point Capital
+ 86 more
Also attended Geisel School of Medicine at Dartmouth15
Jeffrey DeFlavio, MDEntrepreneur in Residence at AlleyCorpNick PliamVenture Partner at Decheng CapitalRyan GreeneMedical Director at Seaside VenturesDavid WasherInvestor at Adjuvant CapitalAuriel AugustPrincipal at Sante VenturesDave PraharajSenior Associate at Global BioAccess Fund
+ 9 more
Also attended The University of North Carolina at Chapel Hill491
Clint MyersInvestor at RevolutionMahati SridharPartner, Rise of the Rest at RevolutionEric WagnerVP of Research and Data at Redpoint VenturesSoul DayanInvestor at True VenturesAlex LimInvestor at IVP (Institutional Venture Partners)Alex TaubPrincipal at QED Investors
+ 485 more
Shared employers
Also worked at Bellicum Pharmaceuticals, Inc.5
Reid HuberPartner at Third Rock VenturesKevin M. SlawinFounder and Managing Partner at Rapha Capital Management, LLCBill GrossmanCo-founder, Strategic Advisor at OnckoHenri BayleFounder at NKILT TherapeuticsDevin BlassChief Technology Officer and Senior Vice President of Chemistry, Manufacturing, and Controls at Longeveron
Also worked at AbbVie67
Nick GasbarroChief of Staff at QED InvestorsCharles White, Ph.D.Principal at Illumina VenturesLaura QuockCBO-in-Residence at Versant VenturesManik PasrichaVice President at Titan CapitalJennifer SmoterChief Communications & Governance Officer at Takeda VenturesTakehiko SawabeDirector at Beyond Next Ventures
+ 61 more
Also worked at Pharmacyclics, an AbbVie Company13
Maria FardisVenture Partner at Frazier Life SciencesManmeet SoniExecutive Officer, Director at Summit TherapeuticsRichard A. MillerPresident & CEO, Co-Founder at CorvuspharmaMark K OkiExecutive Officer at Alexza PharmaceuticalsCynthia BamdadPresident & Chief Executive Officer at Minerva BiotechnologiesMarkus RenschlerDirector at Cyteir Therapeutics
+ 7 more
Also worked at Amgen189
Parker ConradCo-founder & CEO of RipplingSeth LieblichInvestment Team at 8VCSean BruichChief Technology Officer at Flare Capital PartnersSteph ScottVice President at Questa CapitalBeth SeidenbergFounding Managing Director at Westlake Village BioPartnersKelli McKeirnanDirector of Administration at Westlake Village BioPartners
+ 183 more